HIF inhibition in metastatic renal cell carcinoma (mRCC): Final results of a phase Ib/IIa clinical trial evaluating the nanoparticle drug conjugate (NDC), CRLX101, in combination with bevacizumab (bev).

被引：22

作者：

Keefe, Stephen Michael

Hoffman-Censits, Jean H.

Mamtani, Ronac

Walicki, Mary

Robinson, Janelle

Smith, Abigail

Gunnarsson, Orvar

Piscitelli, Anthony

Hennessey, Meliessa

Jayaraman, Lata

Nixon, Andrew B.

Eliasof, Scott

Cohen, Roger B.

Vaughn, David J.

Garmey, Edward Graeme

Haas, Naomi B.

机构：

[1] Hosp Univ Penn, Philadelphia, PA 19104 USA

[2] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA

[3] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[4] Univ Penn, Philadelphia, PA 19104 USA

[5] Cerulean Pharma, Cambridge, MA USA

[6] Cerulean Pharma Inc, Cambridge, MA USA

[7] Duke Univ Med Ctr, Durham, NC USA

来源：

关键词：

D O I：

10.1200/jco.2015.33.15_suppl.4543

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4543

引用

页数：1